Tanshinone IIBCAS# 17397-93-2 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 17397-93-2 | SDF | Download SDF |
PubChem ID | 9926694 | Appearance | Red powder |
Formula | C19H18O4 | M.Wt | 310.4 |
Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
Synonyms | TanshinoneIIB | ||
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (6S)-6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7H-naphtho[1,2-g][1]benzofuran-10,11-dione | ||
SMILES | CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)CO | ||
Standard InChIKey | XDUXBBDRILEIEZ-LJQANCHMSA-N | ||
Standard InChI | InChI=1S/C19H18O4/c1-10-8-23-18-12-5-6-13-11(4-3-7-19(13,2)9-20)15(12)17(22)16(21)14(10)18/h5-6,8,20H,3-4,7,9H2,1-2H3/t19-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Co-treatment with Tanshinone IIB (TSB) significantly inhibits the DNA laddering, cytotoxicity and apoptosis of rat cortical neurons induced by staurosporine in a concentration-dependent manner; TSB also suppresses the elevated Bax protein and decreased bcl-2 and caspase-3 proteins induced by staurosporine in rat cortical neurons; TSB is effective in reducing stroke-induced brain damage and may represent a novel drug candidate for further development. TSB significantly inhibits the uptake of digoxin and vinblastine in membrane vesicles containing PgP or MRP1, moderately stimulates PgP ATPase activity, suggesting TSB is a substrate for PgP and MRP1 and that drug resistance to TSB therapy and drug interactions may occur through PgP and MRP1 modulation. |
Targets | P-gp | Bcl-2/Bax | Caspase | ATPase |
In vitro | Involvement of P-glycoprotein and multidrug resistance associated protein 1 in the transport of tanshinone IIB, a primary active diterpenoid quinone from the roots of Salvia miltiorrhiza, across the blood-brain barrier.[Pubmed: 19356045]Drug Metab Lett. 2007 Aug;1(3):205-17.Tanshinone IIB (TSB) is a major constituent of Salvia miltiorrhiza, which is widely used in treatment of cardiovascular and central nervous system (CNS) diseases such as coronary heart disease and stroke. This study aimed to investigate the role of various drug transporters in the brain penetration of Tanshinone IIB using several in vitro and in vivo mouse and rat models. Tanshinone IIB, a primary active constituent from Salvia miltiorrhiza, exerts neuroprotective effect via inhibition of neuronal apoptosis in vitro.[Pubmed: 18389485 ]Phytother Res. 2008 Jun;22(6):846-50.Tanshinone IIB (TSB) is a major active constituent of the roots of Salvia miltiorrhiza (Danshen) widely used in the treatment of stroke and coronary heart disease in Asian countries. |
Tanshinone IIB Dilution Calculator
Tanshinone IIB Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.2216 mL | 16.1082 mL | 32.2165 mL | 64.433 mL | 80.5412 mL |
5 mM | 0.6443 mL | 3.2216 mL | 6.4433 mL | 12.8866 mL | 16.1082 mL |
10 mM | 0.3222 mL | 1.6108 mL | 3.2216 mL | 6.4433 mL | 8.0541 mL |
50 mM | 0.0644 mL | 0.3222 mL | 0.6443 mL | 1.2887 mL | 1.6108 mL |
100 mM | 0.0322 mL | 0.1611 mL | 0.3222 mL | 0.6443 mL | 0.8054 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- SYM 2206
Catalog No.:BCC6866
CAS No.:173952-44-8
- Isogambogenin
Catalog No.:BCN3066
CAS No.:173938-23-3
- Atrasentan
Catalog No.:BCC1379
CAS No.:173937-91-2
- Gambogenic acid
Catalog No.:BCN3077
CAS No.:173932-75-7
- Corynoxine B
Catalog No.:BCN8454
CAS No.:17391-18-3
- Isocarapanaubine
Catalog No.:BCN1117
CAS No.:17391-09-2
- FR 171113
Catalog No.:BCC7734
CAS No.:173904-50-2
- Y-39983 dihydrochloride
Catalog No.:BCC4186
CAS No.:173897-44-4
- Swertiamarin
Catalog No.:BCN1116
CAS No.:17388-39-5
- H-Leu-OBzl.TosOH
Catalog No.:BCC2970
CAS No.:1738-77-8
- H-Gly-OBzl.TosOH
Catalog No.:BCC2948
CAS No.:1738-76-7
- H-Ser-OBzl.HCl
Catalog No.:BCC3030
CAS No.:1738-72-3
- 22-Hydroxy-3-oxo-12-ursen-30-oic acid
Catalog No.:BCN1526
CAS No.:173991-81-6
- 5-Acetyl-6-hydroxy-2-(1-hydroxy-1-methylethyl)benzofuran
Catalog No.:BCN7495
CAS No.:173992-05-7
- Nepicastat
Catalog No.:BCC1795
CAS No.:173997-05-2
- Dehydroabietic acid
Catalog No.:BCN1119
CAS No.:1740-19-8
- Bevirimat
Catalog No.:BCC5312
CAS No.:174022-42-5
- Tomatine
Catalog No.:BCN2966
CAS No.:17406-45-0
- 3-(4-Pyridyl)-D-Alanine.2HCl
Catalog No.:BCC2650
CAS No.:174096-41-4
- Aristolochic acid D
Catalog No.:BCN2902
CAS No.:17413-38-6
- 3-Chloro-4-hydroxypiperidin-2-one
Catalog No.:BCN3992
CAS No.:174204-83-2
- Methyl 3-(2,4-dihydroxyphenyl)propionate
Catalog No.:BCN1525
CAS No.:17422-90-1
- Pancixanthone A
Catalog No.:BCN7379
CAS No.:174232-30-5
- Apigenin 7-O-(2G-rhamnosyl)gentiobioside
Catalog No.:BCN1524
CAS No.:174284-20-9
Involvement of P-glycoprotein and multidrug resistance associated protein 1 in the transport of tanshinone IIB, a primary active diterpenoid quinone from the roots of Salvia miltiorrhiza, across the blood-brain barrier.[Pubmed:19356045]
Drug Metab Lett. 2007 Aug;1(3):205-17.
Tanshinone IIB (TSB) is a major constituent of Salvia miltiorrhiza, which is widely used in treatment of cardiovascular and central nervous system (CNS) diseases such as coronary heart disease and stroke. This study aimed to investigate the role of various drug transporters in the brain penetration of TSB using several in vitro and in vivo mouse and rat models. The uptake and efflux of TSB in rat primary microvascular endothelial cells (RBMVECs) were ATP-dependent and significantly altered in the presence of a P-glycoprotein (P-gp) or multidrug resistance associated protein (Mrp1/2) inhibitor. A polarized transport of TSB was found in RBMVEC monolayers with facilitated efflux from the abluminal to luminal side. Addition of a P-gp inhibitor (e.g. verapamil) in both abluminal and luminal sides attenuated the polarized transport. In an in situ rat brain perfusion model, TSB crossed the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier at a greater rate than that for sucrose, and the brain penetration was increased in the presence of a P-gp or Mrp1/2 inhibitor. The brain levels of TSB were only about 30% of that in the plasma and it could be increased to up to 72% of plasma levels when verapamil, quinidine, or probenecid was co-administered in rats. The entry of TSB to CNS increased by 67-97% in rats subjected to middle cerebral artery occlusion or treatment with the neurotoxin, quinolinic acid, compared to normal rats. Furthermore, The brain levels of TSB in mdr1a(-/-) and mrp1(-/-) mice were 28- to 2.6-fold higher than those in the wild-type mice. TSB has limited brain penetration through the BBB due to the contribution of P-gp and to a lesser extent of Mrp1 in rodents. Further studies are needed to confirm whether these corresponding transporters in humans are involved in limiting the penetration of TSB across the BBB and the clinical relevance.